Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy

Biomaterials

Volumn 51, Issue , 2015, Pages 1-11

  Xu, Cong Fei ^a   Liu, Yang ^b   Shen, Song ^b   Zhu, Yan Hua ^b   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer therapy; Glioma stem cells; Glucose transporter 3; Nanomedicine; SiRNA delivery

Indexed keywords

CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG INTERACTIONS; GLUCOSE; MEDICAL NANOTECHNOLOGY; METABOLISM; NANOPARTICLES; ONCOLOGY; POLYETHYLENE GLYCOLS; STEM CELLS; TUMORS;

CANCER THERAPY; GLUCOSE TRANSPORTERS; INTRAVENOUS INJECTIONS; MICROENVIRONMENTS; POLY(ETHYLENE GLYCOL) B POLY(D ,L LACTIDE); PROLIFERATION INHIBITION; SIRNA DELIVERY; SYSTEMIC DELIVERIES;

TARGETED DRUG DELIVERY;

GLUCOSE TRANSPORTER 3; MACROGOL; POLYLACTIDE; SMALL INTERFERING RNA; GLUCOSE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL METABOLISM; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GLIOMA CELL LINE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CANCER STEM CELL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; GENE SILENCING; GLIOMA; INTRACELLULAR SPACE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENDOCYTOSIS; GENE KNOCKDOWN TECHNIQUES; GLIOMA; GLUCOSE; GLUCOSE TRANSPORTER TYPE 3; HUMANS; INTRACELLULAR SPACE; MICE, INBRED NOD; MICE, SCID; NANOMEDICINE; NANOPARTICLES; NEOPLASTIC STEM CELLS; RNA, SMALL INTERFERING;

EID: 84924865111     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.068     Document Type: Article

References (57)

1. Heiden M.G.V., Cantley L.C., Thompson C.B. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
2. Akahane T., Hirasawa A., Tsuda H., Kataoka F., Nishimura S., Tanaka H., et al. The origin of stroma surrounding epithelial ovarian cancer cells. Int J Gynecol Pathol 2013, 32:26-30.
3. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
4. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20.
5. Tennant D.A., Duran R.V., Boulahbel H., Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009, 30:1269-1280.
6. Chan D.A., Sutphin P.D., Nguyen P., Turcotte S., Lai E.W., Banh A., et al. Targeting GLUT1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011, 3. 94ra70.
7. Jae H.J., Chung J.W., Park H.S., Lee M.J., Lee K.C., Kim H.C., et al. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: invivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J Radiol 2009, 10:596-603.
8. Locasale J.W., Grassian A.R., Melman T., Lyssiotis C.A., Mattaini K.R., Bass A.J., et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011, 43:869-874.
9. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., Deck L.M., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U. S. A 2010, 107:2037-2042.
10. Heiden M.G.V. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011, 10:671-684.
11. Rothlisberger C., Donath A., Poretti G.G., Zuppinger A. Studies on calcium metabolism in humans with the aid of a whole body counter. whole body retention of Ca47 in the healthy and in patients with tumors and other diseases. Radiol Clin Biol 1971, 40:200-211.
12. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci 2013, 16:1373-1382.
13. Hamanaka R.B., Chandel N.S. Targeting glucose metabolism for cancer therapy. JExp Med 2012, 209:211-215.
14. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
15. Szablewski L. Expression of glucose transporters in cancers. Bba Rev Cancer 2013, 1835:164-169.
16. Adekola K., Rosen S.T., Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol 2012, 24:650-654.
17. Yun J.Y., Rago C., Cheong I., Pagliarini R., Angenendt P., Rajagopalan H., et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009, 325:1555-1559.
18. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994, 219:713-725.
19. Flier J.S., Mueckler M., McCall A.L., Lodish H.F. Distribution of glucose transporter messenger RNA transcripts in tissues of rat and man. JClin Invest 1987, 79:657-661.
20. Kahn B.B., Flier J.S. Regulation of glucose-transporter gene expression invitro and invivo. Diabetes Care 1990, 13:548-564.
21. Simpson I.A., Dwyer D., Malide D., Moley K.H., Travis A., Vannucci S.J. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endoc M 2008, 295. E242-E53.
22. Gould G.W., Holman G.D. The glucose transporter family: structure, function and tissue-specific expression. Biochem J 1993, 295:329-341.
23. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
24. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8:511-524.
25. Birsoy K., Possemato R., Lorbeer F.K., Bayraktar E.C., Thiru P., Yucel B., et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014, 508:108-112.
26. Meneses A.M., Medina R.A., Kato S., Pinto M., Jaque M.P., Lizama I., et al. Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75. JCell Physiol 2008, 214:110-116.
27. Ha T.K., Her N.G., Lee M.G., Ryu B.K., Lee J.H., Han J., et al. Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated GLUT3 transcription. Cancer Res 2012, 72:4097-4109.
28. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
29. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
30. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
31. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., et al. Tcell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
32. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
33. Raoul C., Abbas-Terki T., Bensadoun J.C., Guillot S., Haase G., Szulc J., et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11:423-428.
34. McCaffrey A.P., Nakai H., Pandey K., Huang Z., Salazar F.H., Xu H., et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21:639-644.
35. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U. S. A 2003, 100:183-188.
36. Ashley C.E., Carnes E.C., Phillips G.K., Durfee P.N., Buley M.D., Lino C.A., et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 2011, 5:5729-5745.
37. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441:111-114.
38. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
39. Huang L., Liu Y. Invivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011, 13:507-530.
40. Qian X., Long L., Shi Z., Liu C., Qiu M., Sheng J., et al. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials 2014, 35:2322-2335.
41. Zhou J., Patel T.R., Fu M., Bertram J.P., Saltzman W.M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 2012, 33:583-591.
42. Gao L.Y., Liu X.Y., Chen C.J., Wang J.C., Feng Q., Yu M.Z., et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for invivo siRNA delivery. Biomaterials 2014, 35:2066-2078.
43. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated invivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
44. Sun T.M., Du J.Z., Yao Y.D., Mao C.Q., Dou S., Huang S.Y., et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5:1483-1494.
45. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4. 130ra48.
46. Yang X.Z., Dou S., Sun T.M., Mao C.Q., Wang H.X., Wang J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. JControl Release 2011, 156:203-211.
47. Liu Y., Zhu Y.H., Mao C.Q., Dou S., Shen S., Tan Z.B., et al. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. JControl Release 2014, 192C:114-121.
48. Shen S., Mao C.Q., Yang X.Z., Du X.J., Liu Y., Zhu Y.H., et al. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma. Mol Pharm 2014, 11:2612-2622.
49. Yang X.Z., Du J.Z., Dou S., Mao C.Q., Long H.Y., Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 2012, 6:771-781.
50. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013, 13:727-738.
51. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
52. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
53. Burgess E.A., Sylven B. Glucose, lactate, and lactic dehydrogenase activity in normal interstitial fluid and that of solid mouse tumors. Cancer Res 1962, 22:581.
54. Hirayama A., Kami K., Sugimoto M., Sugawara M., Toki N., Onozuka H., et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009, 69:4918-4925.
55. Urasaki Y., Heath L., Xu C.W. Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors. PloS One 2012, 7. e36775.
56. Sena L.A., Chandel N.S. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012, 48:158-167.
57. Graham N.A., Tahmasian M., Kohli B., Komisopoulou E., Zhu M.G., Vivanco I., et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol 2012, 8:589.